Biogen (BIIB) PT Lowered to $275 at BofA Securities
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $221.56 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham lowered the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $295.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
